ArticleGlobal medical genetics2022

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.

Fei-Yu DiaoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.